ХИМИЧЕСКИЙ СИНТЕЗ И АНАЛИЗ АНТИМИКРОБНОЙ И ГЕМОЛИТИЧЕСКОЙ АКТИВНОСТИ СТРУКТУРНОГО АНАЛОГА ПЕПТИДНОГО ПРОТЕГРИНА 1

Полный текст

Introduction. Invention of antibiotics allowed combating to dangerous infections for many years. But nowadays bacteria developed resistance to many antimicrobial compounds using in clinics. A search for new pharmaceuticals for fighting the drug-resistant bacteria is an important goal of medical research. Solving of this problem may be connected with investigation of the endogenous host defense factors such as antimicrobial peptides of the innate immune system. Antimicrobial peptides (AMPs) are cationic molecules with varied structures. High antimicrobial activity of AMPs points to their possible usage as new antimicrobial medications. But there are limitations of the AMPs practical application: many of them are not stable in biological solutions, while others exert some toxicity for host cells, including the hemolytic activity. To overcome these problems the synthetic analogues of natural AMPs are developing for creation new peptides with improved characteristics. The aim of the present work was design, chemical synthesis and examination of antimicrobial and hemolytic activity of structural variants of a peptide protegrin 1 (PG1). Protegrins are beta-hairpin AMPs with marked broad-spectrum antimicrobial activity and high stability in serum [1]. But these peptides exert some hemolytic activity towards human erythrocytes, and therefore may cause side effects in the case their use as an antibiotic drug. We have designed a peptide PG-B7 that includes a disulfide bonded region of PG1 and a fragment of N-terminal region of a caprine bactenecin ChBac7.5. Another PG1 analog - a truncated peptide - PG1 (5-16). And the third analog with the modification in a region from 4 to 11 amino acid residues - PG (4-11 mod). Material and methods. The peptides were produced onthe automatic peptide synthesizer Biotage Initiator Alstra, by Fmoc-tBu strategy on Rink-Amide resin (ChemMatrix, Iris Biotech). Amino acids were crosslinked using diisopropylcarbodiimide/oxyma in dimethylformamide, at 70 °C for 10 minutes. Some cysteine residues were protected by trityl group, while others - by S-acetamidomethyl groups. Removing the peptides from the resin was carried out using trifluoroacetic acid with addition of water, thioanisole, triisopropylsilane; all groups except of S-acetylaminomethyl were detached. At the next step the peptides were analyzed and purified by RP-HPLC. Afterwards they were dissolved in phosphate buffer pH 6 and free cysteines were oxidized by adding a few drops of concentrated hydrogen peroxide. The obtained peptides with linked first S-S bridge were purified using RP-HPLC. Then the simultaneous removal of S-acetylaminomethyl group with linking the second S-S bridge was carried by adding methanol to the final concentration of 50%, with several drops of iodine in methanol. The reaction was performed for 15 to 30 min, monitoring by RP-HPLC. The obtained peptides with two S-S bridges were purified by RP-HPLC and dried down by lyophilization. Antimicrobial activity of the obtained peptides was tested against a set of drug-resistant clinical isolates of bacteria (Acinetobacter baumannii, Klebsella pneumonia, Pseudomonas aeruginosa, E. coli) by use a broth microdilution assay [2]. Hemolytic activity of the peptides towards erythrocytes of healthy donors was estimated as described [3]. Results and discussion. The applied procedure of peptide synthesis allowed obtaining PG1 analogues with 95-98% of purity as was proved by MALDI TOF MS, analytical HPLC and electrophoresis. Examination of the antimicrobial activity of the peptides revealed that the activity of PG-B7 was, in general, similar with that of the parent peptide PG1 and minimal inhibitory concentrations (MICs) were ranged from 0.125 µM to 4 µM against drug-resistant Gram-negative (P. aeruginosa, K. pneumonia, A. baumannii, E. coli) and Gram-positive (S. aureus) bacteria. For the truncated PG1 analogue MICs were somewhat higher (therefore, the activity was lower) and consisted of 0.5 to 8 µM. The activity of the third analogue was low (MICs > 64 µM). The hemolytic activity of PG-B7 was lower than that of PG1: at antimicrobial concentrations 1.6 µM, 3.1 µM, 6.25 µM, 12.5 µM the percentage of lysed red blood cells for PG1 consisted of 17.40 ± 7.54%, 28.88 ± 5.03%, 38.42 ± 8.00%; 61.53 ± 3.66%, respectively; for PG-B7 - 3.83 ± 1.14%, 14.01 ± 4.57%, 27.75 ± 5.71%, 50.38 ± 5.71%; for the truncated PG (5-16) - 0.02 ± 0.29%; 0.06 ± 0.29%; 1.6 ± 0.6%; 5.3 ± 0.6%. At the concentration of 100 µM PG1 as well as its analogues PG-B7 and PG (7-16) exerted a significant hemolytic effect - 77-100%. The analogue PG- had a lack of the hemolytic activity at the range of concentrations 1-100 µM. Conclusion. The obtained results point to the way of a design of PG1 structural analogues with the lowered hemolytic activity and potent antimicrobial action against drug-resistant bacteria.

Об авторах

П М Копейкин

ФГБНУ «Институт экспериментальной медицины»

М С Сухарева

ФГБНУ «Институт экспериментальной медицины»; ФГБНУ ВО «Санкт-Петербургский политехнический университет Петра Великого»

Н В Луговкина

ФГБНУ «Институт экспериментальной медицины»

О В Шамова

ФГБНУ «Институт экспериментальной медицины»

Список литературы

Дополнительные файлы